Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 2/20 | 0.42 |
| ▸ | KIT | P10721 | 2/20 | 0.42 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 2/20 | 0.39 |
| ▸ | STS | P08842 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CDK9 | P50750 | 1/20 | 0.39 |
| ▸ | F12 | P00748 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30339675 | 1.00 | BAZ2B (0.42) | BAZ2BKITMKNK1POLBCNR1 | |
| SCHEMBL404753 | 0.93 | BAZ2B (0.48) | BAZ2BMKNK1MEN1KMT2AESR2 | |
| SCHEMBL31424848 | 0.83 | ESR2 (0.40) | BAZ2BKITMKNK1POLBCNR1 | |
| SCHEMBL30339672 | 0.80 | KIT (0.48) | KITPOLBMAPTCDK9 | |
| SCHEMBL6482914 | 0.80 | CGAS (0.59) | BAZ2BCNR1STSMEN1KMT2A | |
| SCHEMBL24101723 | 0.80 | KIT (0.48) | KITPOLBMAPTCDK9 | |
| SCHEMBL6483420 | 0.80 | BAZ2B (0.45) | BAZ2BCNR1MEN1KMT2AESR2 | |
| SCHEMBL21588363 | 0.80 | CDK9 (0.44) | KITMKNK1ESR2MAPTCDK9 | |
| SCHEMBL30667649 | 0.79 | MAPT (0.46) | BAZ2BMKNK1ESR2MAPT | |
| SCHEMBL24101581 | 0.77 | KDM4E (0.38) | BAZ2BMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227453-A1 | TRICYCLIC PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230227453-A1 | TRICYCLIC PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227453-A1 | TRICYCLIC PSYCHOPLASTOGENS AND USES THEREOF | GAP43, GRIN2A, GRIN2C | BAZ2B 3141/4885KIT 2589/4885MKNK1 1007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.